Grifols (GIFLF) Receivables - Other (2009 - 2025)
Grifols' (GIFLF) quarterly Receivables - Other came in at $117.6 million in Q4 2025, up 41.05% on a YoY basis from $83.4 million in Q4 2024, and up 41.05% quarter-over-quarter from $83.4 million in Q4 2024.
Analysis
Grifols (GIFLF) Receivables - Other (2009 - 2025) Analysis & Trends
Grifols (GIFLF) has reported Receivables - Other for 17 consecutive years, with $117.6 million the latest figure, recorded in Q4 2025.
- For the quarter ending Q4 2025, Receivables - Other rose 41.05% year-over-year to $117.6 million; the trailing twelve-month figure through Dec 2025 stood at $117.6 million (up 41.05% YoY), and the FY2025 full-year result was $114.1 million, up 36.91% from the prior year.
- Receivables - Other improved to $117.6 million in Q4 2025 per GIFLF's latest filing, from $83.4 million in the prior quarter.
- Across five years, Receivables - Other topped out at $117.6 million in Q4 2025 and bottomed at $63.0 million in Q4 2021.
- Historically, Receivables - Other has averaged $83.8 million across 5 years, with a median of $80.6 million in 2023.
- The sharpest annual moves came in 2021 and 2025: Receivables - Other fell 26.99% in 2021, then jumped 41.05% in 2025.
- Over 5 years, Receivables - Other stood at $63.0 million in 2021, then climbed by 18.53% to $74.7 million in 2022, then advanced by 7.98% to $80.6 million in 2023, then gained by 3.38% to $83.4 million in 2024, then soared by 41.05% to $117.6 million in 2025.
- According to Business Quant data, Receivables - Other over the past three periods registered $117.6 million, $83.4 million, and $80.6 million for Q4 2025, Q4 2024, and Q4 2023 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Amgen | 203.97 Bn | 189.99 Bn | 7.24 Bn |
| 2 | Gilead Sciences | 178.74 Bn | 175.56 Bn | 6.22 Bn |
| 3 | Vertex Pharmaceuticals | 130.73 Bn | 122.88 Bn | 2.84 Bn |
| 4 | Regeneron Pharmaceuticals | 80.42 Bn | 72.42 Bn | 3.93 Bn |
| 5 | Argenx Se | 60.40 Bn | 55.21 Bn | 1.37 Bn |
| 6 | Moderna | 57.65 Bn | 52.52 Bn | 52.00 Mn |
| 7 | Alnylam Pharmaceuticals | 33.37 Bn | 30.07 Bn | 992.69 Mn |
| 8 | Biogen | 32.15 Bn | 30.86 Bn | 1.96 Bn |
| 9 | Roivant Sciences | 29.58 Bn | 29.58 Bn | 1.16 Mn |
| 10 | Grifols | 7.54 Bn | 9.09 Bn | 3.33 Bn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2025 | 117.57 Mn |
| Dec 31, 2024 | 83.35 Mn |
| Dec 31, 2023 | 80.62 Mn |
| Dec 31, 2022 | 74.66 Mn |
| Dec 31, 2021 | 62.99 Mn |
| Dec 31, 2020 | 86.27 Mn |
| Dec 31, 2019 | 91.33 Mn |
| Dec 31, 2018 | 105.49 Mn |
| Jun 30, 2018 | 97.98 Mn |
| Dec 31, 2017 | 47.90 Mn |
| Jun 30, 2017 | 66.64 Mn |
| Dec 31, 2016 | 45.67 Mn |
| Sep 30, 2016 | 56.87 Mn |
| Jun 30, 2016 | 70.64 Mn |
| Dec 31, 2015 | 66.34 Mn |
| Sep 30, 2015 | 66.93 Mn |
| Jun 30, 2015 | 66,869.89 |
| Mar 31, 2015 | 57.93 Mn |
| Dec 31, 2014 | 44.21 Mn |
| Sep 30, 2014 | 56.64 Mn |